Hoyer Dieter P, Benkö Tamas, Manka Paul, von Horn Charlotte, Treckmann Juergen W, Paul Andreas, Minor Thomas
General, Visceral and Transplantation Surgery, University Hospital Essen, Germany.
Department of Gastroenterology and Hepatology, University Hospital Essen, Germany.
Transplant Direct. 2020 Mar 13;6(4):e542. doi: 10.1097/TXD.0000000000000987. eCollection 2020 Apr.
Controlled oxygenated rewarming (COR) has been shown to be a feasible and safe method in clinical practice and to reduce peak serum transaminases after liver transplantation. This study aimed to demonstrate further clinical experience of this method of now 18 clinical liver transplantations utilizing COR and demonstrate the long-term results.
In this extended series of 18 patients, cold-stored livers were subjected to machine-assisted slow COR for ≈120 minutes before transplantation. A cohort of 178 patients transplanted during the same period with similar clinical characteristics were used for comparison of key outcomes.
All livers were perfused in accordance to the COR protocol without incidences and transplanted successfully. Early allograft dysfunction was observed in 2 (11.1%) cases after COR. Liver elasticity measurements indicated normal healthy liver parenchyma at the last follow-up. Graft survival demonstrated excellent outcomes after COR. The 1-, 3-, and 5-year patient survival rates were 100%, 100%, and 93.8% compared with 84.5%, 82.0%, and 75.8% in the control group ( = 0.12).
The present study demonstrates excellent clinical outcomes after COR before liver transplantation. Comparison with a control cohort shows superiority of graft survival. Further evidence is needed to assess this promising method to improve organ preservation, finally.
在临床实践中,控制性氧合复温(COR)已被证明是一种可行且安全的方法,并且能降低肝移植后血清转氨酶峰值。本研究旨在进一步展示这种方法(目前已应用于18例临床肝移植)的临床经验,并展示其长期效果。
在这组扩大至18例患者的研究中,冷保存肝脏在移植前接受约120分钟的机器辅助缓慢COR。选取同期移植的178例具有相似临床特征的患者作为对照,比较关键结局指标。
所有肝脏均按照COR方案进行灌注,无不良事件发生,并成功移植。COR后2例(11.1%)出现早期移植物功能障碍。肝脏弹性测量显示,在末次随访时肝实质健康正常。COR后移植物存活情况良好。1年、3年和5年患者生存率分别为100%、100%和93.8%,而对照组分别为84.5%、82.0%和75.8%(P = 0.12)。
本研究证明肝移植前COR具有良好的临床效果。与对照组比较显示移植物存活方面具有优势。最终还需要进一步证据来评估这种有前景的改善器官保存的方法。